Pharma BD Deal Intelligence
Lilly maintains deal streak with $1.2B pact for Hanmi's GLP-2 candidate — The agreement adds a rare gastrointestinal asset to Lilly's expanding portfolio, with…
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger…
Eli Lilly Signs Up to $1.2B Licensing Deal for Hanmi GLP-2 Therapy in Short Bowel Syndrome — Eli Lilly obtained worldwide rights to sonefpeglutide, a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
On June 1, 2026, Eli Lilly licensed global rights (outside Korea) to sonefpeglutide, Hanmi Pharmaceutical's long-acting GLP-2 receptor agonist, in a deal worth up to approximately $1.26 billion. Hanmi receives $75 million upfront and is eligible for up to $1.185 billion in clinical, regulatory and commercial milestone payments plus tiered royalties. The lead indication is short bowel syndrome, a rare malabsorption disorder; Hanmi has an ongoing U.S. Phase 2 study (DOLPHINS-2), and Lilly will explore additional gastrointestinal indications. The deal extends Lilly's gastrointestinal and incretin-biology franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. (this deal) | 2026 | $1.3B | 65 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Rare Disease deals